WINNIPEG, MB / TheNewswire / May 8, 2019 – DELTA 9 CANNABIS INC. (TSXV: NINE) (OTCQX: VRNDF) (“Delta 9” or the “Company”)is pleased to provide investors with an update on the Company’s international activities.
On May 8, 2019, the Company received notice from Health Canada that it has been granted an export permit to sell starting materials to authorized cannabis license holders in Australia and Tasmania. The permit will allow the Company to complete orders for rooted cannabis plants for international sale.
“Delta 9 has two pending sales contracts for cannabis plants to licensed producers in Australia. The approval of the export license will mark Delta 9’s first international cannabis product sale this quarter”, said John Arbuthnot, CEO, “Our team has worked very hard to secure export permits and we continue to pursue international opportunities to bring Delta 9 products to global markets”
Delta 9 Grow Pods
The Company is reporting that it has also begun marketing and sales of its proprietary “Grow Pod” cultivation systems into the United States and completed its first shipment to a US operator this month.
The Company’s proprietary cannabis production methodology is based around a modular, scalable, and stackable production unit called a grow pod (a “Grow Pod”). The Company builds its Grow Pods by retrofitting standard shipping containers into Grow Pods. The Grow Pods are built to comply with Health Canada security requirements and good production practices and create optimal conditions for production of cannabis while effectively mitigating the risk of crop loss.
EU GMP Certification
The Company continues to pursue EU GMP certification for its Winnipeg based cultivation and processing facilities which will allow for export of medical cannabis flower and oil products into international markets. The Company anticipates receiving its certification within the calendar year 2019.
For more information contact:
Investor & Media Contact:
Ian Chadsey VP Corporate Affairs
About Delta 9 Cannabis Inc.
Delta 9 Cannabis is a vertically integrated cannabis company focused on bringing the highest quality cannabis products to market. Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9 owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. Delta 9’s shares trade on the TSX Venture Exchange under the symbol “NINE” and on the OTC under the symbol VRNDF. For more information, please visit delta9.ca.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer for Forward-Looking Information
Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company’s future business plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: (i) Delta 9’s expansion plans for its Winnipeg production facilities and for its network of retail stores; (ii) Delta 9’s capital raising plans; (iii) Delta 9’s production of cannabis; and (iv) costs for Delta 9’s expansion plans. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including: (i) Delta 9’s ability to raise sufficient capital for its expansion plans; and (ii) Delta 9 obtaining all regulatory approvals, as well as all risk factors set forth in the annual information form of Delta 9 dated May 31, 2018 which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.